查詢結果分析
相關文獻
- 長效吸入型乙二型交感神經興奮劑在治療阻塞性肺病的臨床應用
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- Pharmacokinetics of Sustain-Released Theophylline in Asthmatic Patients With Nocturnal Dyspnea
- Influence of Morning or Evening Administration on Absorption of Theophylline
- Improvement of Outcomes and Tapering off Corticosteroids in Patients with Chronic Obstructive Airway Disease Using Spirometry Measurements
- 頑固性氣喘(Difficult Asthma)
- Added Salmeterol Versus Higher-Dose Inhaled Steroids in Symptomatic Asthma Patients Already Using Inhaled Steroids
- 氣喘及慢性阻塞性肺疾病患者的睡眠
- Pharmacokinetics of Sustain-Released Theophylline in Asthmatic Patients with Nocturnal Dyspnea
- Sustained-Release Theophylline - Uniphyllin in Nocturnal Asthmatics
頁籤選單縮合
題 名 | 長效吸入型乙二型交感神經興奮劑在治療阻塞性肺病的臨床應用=Clinical Application of Inhaled Long-acting Beta-2 Agonists for Obstructive Airway Diseases |
---|---|
作 者 | 朱遠志; 薛尊仁; | 書刊名 | 內科學誌 |
卷 期 | 13:6 2002.12[民91.12] |
頁 次 | 頁269-275 |
分類號 | 418.21 |
關鍵詞 | 長效吸入型乙二型交感神經興奮劑; 氣喘; 慢性阻塞性肺疾病; 吸入型類固醇; 茶鹼; 白三烯素拮抗劑; Long-acting β[feaf]-agonist; LABA; Asthma; Chronic obstructive pulmonary disease; Inhaled corticosteroid; ICS; Theophylline; Leukotriene receptor antagonist; |
語 文 | 中文(Chinese) |
中文摘要 | 長效吸入型乙二型交感神經興奮劑,對於呼吸道支氣管擴張,具有高度局部選擇性,極少有全身的副作用。目前在市面上有兩種藥物:Salmeterol及Formoterol,此二種藥品使用一次可以持續12小時,藥效相當長。除了Fomoterol作用較快速外,其餘在臨床上的效果此二藥品相當。在氣喘病人的治療方面,長效吸入型乙二型交感神經興奮劑,不僅可以減少氣喘症狀,更可以減少口服或吸入型類固醇的使用劑量。此類藥物合併吸入型類固醇,可以達到加成的作用,且不會影響抗發炎效果,尤其是此二類藥物加在同一個吸入器時,效果更佳,但是,因為長效吸入型乙二型交感神經興奮劑本身只有輕微抗發炎作用,所以不可以單獨使用於氣喘病患。在慢性阻塞性肺疾病的治療上,角色較不明確。但在目前GOLD治療共識上,長效吸入型乙二型交感神經興奮劑,可以用於穩定且中度到嚴重程度肺功能障礙的病人身上。它們不只可以減輕此類病人的症狀,更可以改善肺功 能及生活品質,但對於原先有心律不整的病人應小心使用,可能會併發加重心律不整。同時必須注意的是,對於動脈血氧含量在59毫米汞柱的病人,在使用此類藥品後,可能會有短暫的血氧降低情形。即使有上述的副作用,長效吸入型乙二型交感神經興奮劑在臨床應用上,效果可與抗乙瞌膽鹼藥物並列,或許甚至更好,須要後績的觀察。 總結長效吸入型乙二型交感神經興奮劑,可以用於改善中度持續到重度持續氣喘病人的症狀及肺功能,但必須合併吸入型類固醇使用,二者有加成的效果。對於治療慢性阻塞,肺疾病方面,可用於穩定且中度到嚴重程度肺功能障礙的病人身上,其療效可與抗乙瞌膽鹼藥物並列,而且效果持續較久且醫囑性更佳。 |
英文摘要 | Long-acting (32 agonists (LABA) are highly selective for relaxation of smooth muscle of bronchial wall. Inhaled form of LABA can produce local effect of bronchial tree, and less systemic effect. At present, two products of inhaled LABA are Salmeterol, and Formoterol. They had 12 hours duration of bronchial wall dilatation after inhaled. In clinical effects of these two drugs are similar, except Formoterol is rapid onset. For management of patients with asthma, LABA can decrease symptoms and signs, active glucocorticosteroid receptors, and decrease doses of inhaled corticosteroid. It could not administrate lonely due to little anti-inflammation effect. Combination of LABA and ICS in one device can improve lung function in moderate to severe persistent patients. Combination is superior or equal to concurrent therapy via two devices. LABA did not mask inflammation of airway and produce tolerance of short-acting (32 agonists in long-term using. For management of patients with chronic obstructive pulmonary disease (COPD), LABA role is not really clear at present. According GOLD criteria, they can prescribe for moderate to severe patients. LABA can decrease symptoms and signs, and improve lung function and quality of life in long-term using. LABA may induce cardiac arrhythmia in patients pre-existing arrhythmia and transient hypoxemia in patients with Pa02 >59 mmHg. In spite of these adverse effects, they are superior or equal to anticholinergics in management of COPD. LABA are first choice for management of patients with poor control COPD. In conclusions, LABA can free symptoms and sings and improve lung function in moderate to severe persistent asthma. Combination is superior or equal to concurrent therapy in patents with asthma. LABA or anticholinergics can consider first choice therapy drugs in patients with moderate to severe COPD. |
本系統中英文摘要資訊取自各篇刊載內容。